Adagrasib“ing” the Opportunity: Latest Updates from the G12C Inhibitor for Combatting NSCLC & Other Cancers

Time: 9:00 am
day: Conference Day One


  • Studying the single agent effect of Adagrasib to understand its potential and allow researchers to develop more effective cancer therapies
  • Describing various combinations in the clinic and comparing their performance to enable tailored cancer therapy
  • Evaluating in-market considerations and future directions for Adagrasib to expand standard of cancer care, and improve patients’ access to cutting-edge treatments